Galmed Pharmaceuticals and ItamarTM Medical to Collaborate on Assessing Aramchol’s Effect on Endothelial Function.

TEL-AVIV, Israel, Sept. 29, 2014 /PRNewswire/ — Galmed Pharmaceuticals Ltd. GLMD, -1.30% (“Galmed”), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it purchased 60 EndoPAT™ devices and accessories from Itamar Medical Ltd. (tase:ITMR) (“Itamar Medical”), a publicly-traded medical device company whose technology has been cleared by the U.S. Food and Drug Administration, or the FDA, for endothelial, or arterial, function assessment, which is a novel risk marker for cardiovascular disease.